Wall Street analysts predict that Abbott Laboratories (NYSE:ABT) will announce $6.66 billion in sales for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Abbott Laboratories’ earnings. The highest sales estimate is $6.80 billion and the lowest is $6.57 billion. Abbott Laboratories reported sales of $5.30 billion in the same quarter last year, which would suggest a positive year over year growth rate of 25.7%. The firm is expected to announce its next earnings report on Wednesday, October 18th.

On average, analysts expect that Abbott Laboratories will report full-year sales of $6.66 billion for the current fiscal year, with estimates ranging from $26.06 billion to $26.77 billion. For the next year, analysts forecast that the business will post sales of $27.69 billion per share, with estimates ranging from $27.38 billion to $28.18 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Abbott Laboratories had a return on equity of 15.53% and a net margin of 4.96%. The company had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. During the same period last year, the business posted $0.55 earnings per share. The firm’s revenue was up 24.5% compared to the same quarter last year.

ABT has been the subject of several analyst reports. TheStreet raised Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Abbott Laboratories in a research report on Monday, May 15th. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Abbott Laboratories in a research report on Friday, May 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $49.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, April 18th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $48.00 price objective on shares of Abbott Laboratories in a research report on Thursday, April 13th. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $52.13.

In other Abbott Laboratories news, insider Jared Watkin sold 552 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total transaction of $26,479.44. Following the transaction, the insider now owns 47,090 shares of the company’s stock, valued at approximately $2,258,907.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Roger Bird sold 5,600 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $43.82, for a total value of $245,392.00. Following the transaction, the insider now directly owns 51,313 shares in the company, valued at approximately $2,248,535.66. The disclosure for this sale can be found here. In the last quarter, insiders have sold 206,902 shares of company stock worth $9,497,761. 0.76% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ABT. Oxbow Advisors LLC raised its position in shares of Abbott Laboratories by 2.3% in the second quarter. Oxbow Advisors LLC now owns 7,074 shares of the healthcare product maker’s stock valued at $344,000 after buying an additional 156 shares during the period. Duncker Streett & Co. Inc. raised its position in shares of Abbott Laboratories by 1.7% in the second quarter. Duncker Streett & Co. Inc. now owns 59,133 shares of the healthcare product maker’s stock valued at $2,874,000 after buying an additional 1,003 shares during the period. Bridges Investment Counsel Inc. raised its position in shares of Abbott Laboratories by 129.1% in the second quarter. Bridges Investment Counsel Inc. now owns 58,792 shares of the healthcare product maker’s stock valued at $2,857,000 after buying an additional 33,125 shares during the period. Bridges Investment Management Inc. raised its position in shares of Abbott Laboratories by 4.3% in the second quarter. Bridges Investment Management Inc. now owns 39,625 shares of the healthcare product maker’s stock valued at $1,926,000 after buying an additional 1,623 shares during the period. Finally, Private Bank & Trust Co. raised its position in shares of Abbott Laboratories by 12.3% in the second quarter. Private Bank & Trust Co. now owns 30,322 shares of the healthcare product maker’s stock valued at $1,473,000 after buying an additional 3,330 shares during the period. 71.02% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/23/abbott-laboratories-nyseabt-expected-to-post-quarterly-sales-of-6-66-billion.html.

Abbott Laboratories (ABT) traded down 0.02% during midday trading on Friday, reaching $50.84. The company’s stock had a trading volume of 7,980,288 shares. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $51.13. The stock’s 50-day moving average price is $48.18 and its 200 day moving average price is $44.68. The firm has a market capitalization of $88.22 billion, a PE ratio of 71.20 and a beta of 1.07.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a yield of 2.08%. The ex-dividend date is Wednesday, July 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 149.30%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.